title: Identification of sites in adenovirus hexon for foreign peptide incorporation.
abstract: Adenovirus type 5 (Ad5) is one of the most promising vectors for gene therapy applications. Genetic engineering of Ad5 capsid proteins has been employed to redirect vector tropism, to enhance infectivity, or to circumvent preexisting host immunity. As the most abundant capsid protein, hexon modification is particularly attractive. However, genetic modification of hexon often results in failure of rescuing viable viruses. Since hypervariable regions (HVRs) are nonconserved among hexons of different serotypes, we investigated whether the HVRs could be used for genetic modification of hexon by incorporating oligonucleotides encoding six histidine residues (His6) into different HVRs in the Ad5 genome. The modified viruses were successfully rescued, and the yields of viral production were similar to that of unmodified Ad5. A thermostability assay suggested the modified viruses were stable. The His6 epitopes were expressed in all modified hexon proteins as assessed by Western blotting assay, although the intensity of the reactive bands varied. In addition, we examined the binding activity of anti-His tag antibody to the intact virions with the enzyme-linked immunosorbent assay and found the His6 epitopes incorporated in HVR2 and HVR5 could bind to anti-His tag antibody. This suggested the His6 epitopes in HVR2 and HVR5 were exposed on virion surfaces. Finally, we examined the infectivities of the modified Ad vectors. The His6 epitopes did not affect the native infectivity of Ad5 vectors. In addition, the His6 epitopes did not appear to mediate His6-dependent viral infection, as assessed in two His6 artificial receptor systems. Our study provided valuable information for studies involving hexon modification.
authors.affiliation: Division of Human Gene Therapy, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
authors.forename: Hongju
authors.initials: H
authors.lastname: Wu
authors.forename: Tie
authors.initials: T
authors.lastname: Han
authors.forename: Natalya
authors.initials: N
authors.lastname: Belousova
authors.forename: Victor
authors.initials: V
authors.lastname: Krasnykh
authors.forename: Elena
authors.initials: E
authors.lastname: Kashentseva
authors.forename: Igor
authors.initials: I
authors.lastname: Dmitriev
authors.forename: Manjula
authors.initials: M
authors.lastname: Kataram
authors.forename: Parameshwar J
authors.initials: PJ
authors.lastname: Mahasreshti
authors.forename: David T
authors.initials: DT
authors.lastname: Curiel
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000254:growth & development; D015153:Blotting, Western; D036022:Capsid Proteins / Q000737:chemistry* / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes; D018014:Gene Transfer Techniques; D005814:Genes, Viral; D005822:Genetic Vectors; D006367:HeLa Cells; D006801:Humans; D009841:Oligonucleotides / Q000235:genetics; D009842:Oligopeptides / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D013696:Temperature
chemical_list: D036022:Capsid Proteins; D000939:Epitopes; D009841:Oligonucleotides; D009842:Oligopeptides; D011993:Recombinant Fusion Proteins; C018315:hexon capsid protein, Adenovirus
references.citation: J Virol. 1999 Aug;73(8):6729-42
references.pmid: 10400771
references.citation: J Mol Biol. 1994 Sep 30;242(4):430-55
references.pmid: 7932702
references.citation: J Virol. 2002 Jul;76(14):6893-9
references.pmid: 12072490
references.citation: Trends Microbiol. 2000 Sep;8(9):391-4
references.pmid: 10989301
references.citation: J Virol. 1993 Sep;67(9):5198-205
references.pmid: 8350395
references.citation: Nat Biotechnol. 1999 May;17(5):470-5
references.pmid: 10331807
references.citation: Eur J Cancer. 2002 Sep;38(14):1917-26
references.pmid: 12204675
references.citation: J Virol. 2002 Jan;76(1):127-35
references.pmid: 11739678
references.citation: Oncologist. 2002;7(1):46-59
references.pmid: 11854546
references.citation: Gene Ther. 1999 Sep;6(9):1558-64
references.pmid: 10490765
references.citation: Cancer Gene Ther. 2000 Oct;7(10):1329-35
references.pmid: 11059690
references.citation: J Virol. 1998 Dec;72(12):10260-4
references.pmid: 9811772
references.citation: BioDrugs. 2002;16(1):3-10
references.pmid: 11908997
references.citation: J Virol. 1994 Jun;68(6):4104-6
references.pmid: 8189552
references.citation: J Mol Biol. 1987 Nov 5;198(1):73-89
references.pmid: 3430605
references.citation: J Virol. 2002 May;76(9):4580-90
references.pmid: 11932423
references.citation: Cell. 1993 Apr 23;73(2):309-19
references.pmid: 8477447
references.citation: J Virol. 1998 Mar;72(3):2388-97
references.pmid: 9499099
references.citation: J Gen Virol. 1999 Jun;80 ( Pt 6):1519-1527
references.pmid: 10374971
references.citation: Science. 1986 May 30;232(4754):1148-51
references.pmid: 3704642
references.citation: Biochim Biophys Acta. 1997 Nov 13;1330(1):8-16
references.pmid: 9375808
references.citation: Hum Mol Genet. 1996 Nov;5(11):1703-12
references.pmid: 8922997
references.citation: Science. 1997 Feb 28;275(5304):1320-3
references.pmid: 9036860
references.citation: J Virol. 2002 Dec;76(24):12775-82
references.pmid: 12438602
references.citation: Microbiol Mol Biol Rev. 1999 Sep;63(3):725-34
references.pmid: 10477314
references.citation: Mol Ther. 2000 Jan;1(1):18-30
references.pmid: 10933908
references.citation: Curr Top Microbiol Immunol. 1995;199 ( Pt 1):47-66
references.pmid: 7555060
references.citation: Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1401-5
references.pmid: 7877990
references.citation: J Gene Med. 2003 Apr;5(4):267-76
references.pmid: 12692861
references.citation: J Virol. 1996 Apr;70(4):2116-23
references.pmid: 8642632
references.citation: Gene Ther. 2002 Aug;9(16):1101-8
references.pmid: 12140738
references.citation: Gene Ther. 1996 Jun;3(6):496-502
references.pmid: 8789799
references.citation: J Virol. 1988 Jul;62(7):2321-8
references.pmid: 3373570
references.citation: J Virol. 1997 Nov;71(11):8221-9
references.pmid: 9343173
references.citation: Virology. 2002 Feb 15;293(2):210-6
references.pmid: 11886240
references.citation: J Virol. 1998 Aug;72(8):6875-9
references.pmid: 9658137
references.citation: J Virol. 1995 Apr;69(4):2004-15
references.pmid: 7884845
references.citation: Curr Top Microbiol Immunol. 1995;199 ( Pt 1):25-38
references.pmid: 7555058
references.citation: J Virol. 1998 Dec;72(12):9706-13
references.pmid: 9811704
references.citation: J Gen Virol. 1994 Jan;75 ( Pt 1):133-9
references.pmid: 7509367
references.citation: J Virol. 1996 Mar;70(3):1836-44
references.pmid: 8627708
references.citation: J Virol. 2003 Sep;77(17):9553-66
references.pmid: 12915569
references.citation: Mol Imaging. 2004 Apr;3(2):105-16
references.pmid: 15296675
references.citation: Hum Gene Ther. 2002 Sep 1;13(13):1647-53
references.pmid: 12228019
references.citation: Hum Gene Ther. 1992 Apr;3(2):147-54
references.pmid: 1391034
references.citation: Nat Biotechnol. 1996 Nov;14(11):1570-3
references.pmid: 9634823
references.citation: Hum Gene Ther. 1999 May 20;10(8):1349-58
references.pmid: 10365665
references.citation: Hum Gene Ther. 2002 Jan 20;13(2):311-20
references.pmid: 11812286
references.citation: Biochim Biophys Acta. 2002 May 3;1575(1-3):1-14
references.pmid: 12020813
references.citation: J Virol. 1999 Jun;73(6):5156-61
references.pmid: 10233980
references.citation: Virology. 1973 Mar;52(1):130-47
references.pmid: 4139804